Phone: 888-558-5227

651-644-8424

888-558-7329 Fax:

Email: getinfo@lktlabs.com lktlabs.com Web:

## **Product Information**

Product ID W9600

CAS No. 1213269-23-8

**Chemical Name** 

Synonym

Formula C<sub>25</sub>H<sub>27</sub>CIN<sub>6</sub>O<sub>3</sub>

Formula Wt. 494.97

**Melting Point** 

Purity ≥98%

Solubility DMSO 13 mg/mL (26.3 mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description WZ-4002 inhibits EGFR in a variety of cell lines, including those harboring the T790M gatekeeper mutation. WZ-2004 exhibits anticancer chemotherapeutic activity, inhibiting proliferation of lung adenocarcinoma cells and suppressing tumor growth in

animal models.

ŃΗ

## **Pricing and Availability**

## Bulk quanitites available upon request

Product ID	Size	<b>List Price</b>
W9600	1 mg	\$68.80
W9600	5 mg	\$129.00
W9600	25 mg	\$326.20
W9600	100 mg	\$1099.90

References Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.

> Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.